Aging is inevitable. Feeling many
of the effects can be preventable.
And we’re working to make it doable.

We’re advancing our three founders’ mission with all we’ve got. Here’s who we are:

John Walker

Chairman of the Board

John P. Walker, has spent his career in Healthcare. He started at American Hospital Supply Corporation, where he eventually became President of the Hospital Company, the largest operating unit of the Corporation. He then moved to the Bay Area, where over the last 30 years, he’s been Chairman, Executive Chairman or CEO of a number of companies including Vitaphore Corporation (sold to Union Carbide), Arris (AXYS) Pharmaceuticals (sold to Celera), Kai Pharmaceuticals (sold to Amgen), Guava Technologies (sold to Millipore Corporation), Signal Pharmaceuticals, (sold to Celgene), Novacea Corporation (merged with Transcept) and iPierian Corporation (sold to BMS). Most recently, John was a founder and Managing Director of Four Oaks Partners, a business advisory firm. He currently serves on the BOD of Lucile Packard Children’s Hospital at Stanford, Packard Children’s Health Alliance, and Random Acts of Flowers, a non-profit that repurposes flowers for delivery to patients at hospitals and long term care facilities.

William Moore, Ph.D.

President & Chief Executive Officer

A business and scientific leader in pharmaceutical and biotechnology R&D, Dr. Moore has devoted his 25-year career to championing new chemical entities from discovery to the clinic (the pharmaceutical industry ‘Valley of Death’) for the treatment of asthma, osteoporosis, inflammatory diseases, and particularly oncology.  Dr. Moore has held key positions such as Chief Executive Officer, President, Director and Chief Scientific Officer for companies that include Arris, Axys, Locus Pharmaceuticals, and most recently, Innocrin Pharmaceuticals (2014-2017). Dr. Moore’s responsibilities have included the evolution of corporate strategy, business development, management of external alliances, intellectual property, fundraising and all aspects of R&D and technology innovation.

Dr. Moore has a B.S. degree in chemistry from Southeastern Massachusetts University, a Ph.D. degree in chemistry from Brown University and, prior to joining the pharmaceutical industry, was a Winston Fellow and Assistant Professor in Biochemistry at Cornell University Medical College.

George Cox, Ph.D., J.D.

Chief Legal Officer & Corporate Secretary

Dr. George Cox brings more than 30 years of combined science and legal experience to Vizuri Health Sciences. Prior to joining Vizuri, Dr. Cox was in private practice at IP & Business Law Counseling, LLC. Before attending law school, he enjoyed a 20-year career as a biomedical scientist and medical school professor at the National Cancer Institute and the Uniformed Services University of the Health Sciences. He’s authored more than 70 publications in diverse scientific disciplines including pharmacology, immunology, biochemistry, and cell and molecular biology.

Dr. Cox earned his B.A. degree in chemistry and zoology from Ohio Wesleyan University, his Ph.D. degree in pharmacology from The Ohio State University College of Medicine, and his J.D. degree from The American University Washington College of Law.

John Todhunter, Ph.D.

Chief Scientific Officer

Dr. John Todhunter has more than 30 years of experience in regulatory affairs, clinical and non-clinical drug testing, strategic development, and quality assurance for drugs and devices. He founded SRS International Corporation and is its President and Director of Biomedical and Regulatory Affairs. Dr. Todhunter served as a Senate-confirmed presidential appointee in charge of all toxic chemical and pesticide programs at the U.S. EPA and was Chair of the Interdepartmental Biochemistry Program at The Catholic University of America. He received his Ph.D. in biochemistry from U.C. Santa Barbara, an bio-organic chemistry from the California State University at Los Angeles, and his B.S. in chemistry from UCLA. A member of the American College of Clinical Pharmacology, Diplomate of the American Board of Forensic Examiners, and Regulatory Affairs Certified by the Regulatory Affairs Professionals certification board, Dr. Todhunter has published numerous articles in the peer reviewed scientific literature and has submitted over 500 studies and/or regulatory submissions to U.S. FDA and EPA.

Michael Billard

VP, Project Management & Operations

Mike is a leader skilled in project management, problem solving, cross-functional team building, and change management.  He led a group of project managers supporting contract development and manufacturing of biopharmaceuticals in his latest position as Vice President, Project Management for Paragon Bioservices.  Previously, Mike served as Senior Director, Project Management for DSM Nutritional Products (formerly Martek Biosciences) where he established and ran a Project Management Office primarily responsible for new product development and operations projects. He was also instrumental in the integrations of both Martek Biosciences and Ocean Nutrition Canada into DSM following their acquisitions.  Prior to joining DSM, Mike was a project manager in roles of increasing responsibility with MedImmune, Inc. and Baxter Healthcare Corporation.

Mike holds a B.S. in Chemistry from Illinois State University and a M.S. in Biotechnology from The Johns Hopkins University.

Matthew Sharp, Ph.D.

Vice President of Pharmaceutical Products

Dr. Matt Sharp brings more than 25 years of pharmaceutical product development experience to Vizuri Health Sciences.  Prior to joining Vizuri he was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Innocrin Pharmaceuticals.  Previously, he held a number of positions of increasing responsibility with GlaxoSmithKline (GSK), most recently serving as U.S. Head of Process Robustness and 2nd Generation, Active Pharmaceutical Ingredients (APIs).  In these roles he was responsible for the development and manufacture of APIs as well as finished drug products.  He has extensive experience in the manufacturing of drug products, research and development, process development, cGMP manufacturing, analytical development and quality systems.

In preparation for his pharmaceutical career, Matt received a B.Sc. degree in Chemistry from Sheffield City (England) Polytech, a M.Sc. in Organic Chemistry from the University of Waterloo (Canada), a Ph.D. in Organic Chemistry from the University of California, Irvine, and then trained as postdoctoral research fellow at the University of California, Berkeley.